Marina Biotech, Inc. announced today that it has entered into a
license agreement with Tekmira Pharmaceuticals Corporation TKMR, where Marina will provide Tekmira a worldwide,
non-exclusive license to Marina Biotech's Unlocked Nucleobase Analog
(UNA) technology for the development of RNA interference
therapeutics. Tekmira will have full responsibility for the
development and commercialization of any products arising under the
Agreement. Under terms of the Agreement, Marina Biotech will receive
an upfront payment plus milestone and royalty payments on products
developed by Tekmira that use UNA technology. Further terms of the
Agreement were not disclosed.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in